Valuation: Grifols, S.A.

Capitalization 5.49B 5.8B 5.09B 4.55B 8.22B 492B 9.01B 63.25B 23.38B 202B 21.78B 21.29B 878B P/E ratio 2024 *
27.3x
P/E ratio 2025 * 9.96x
Enterprise value 15.04B 15.87B 13.95B 12.45B 22.49B 1,347B 24.66B 173B 64.01B 553B 59.64B 58.29B 2,403B EV / Sales 2024 *
2.11x
EV / Sales 2025 * 1.88x
Free-Float
79.4%
Yield 2024 *
-
Yield 2025 * 1.75%
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.02%
1 week+2.18%
Current month+2.18%
1 month-20.90%
3 months-5.39%
6 months-5.82%
Current year-43.03%
More quotes
1 week
8.29
Extreme 8.286
8.87
1 month
8.28
Extreme 8.28
11.30
Current year
6.36
Extreme 6.362
15.63
1 year
6.36
Extreme 6.362
15.92
3 years
6.36
Extreme 6.362
20.28
5 years
6.36
Extreme 6.362
34.31
10 years
6.36
Extreme 6.362
34.31
More quotes
Director TitleAgeSince
Chief Executive Officer 56 2024-03-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Corporate Officer/Principal 68 2016-04-30
Manager TitleAgeSince
Director/Board Member 68 2000-04-12
Chairman 65 2023-02-20
Director/Board Member 61 2001-07-26
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+2.02%+2.18%-37.93%-42.66%5.69B
-0.52%-0.19%+4.61%-8.07%86.88B
-0.94%-2.26%+34.41%+4.27%48.14B
-1.78%-1.81%+137.60%+83.80%37.15B
-0.84%-2.60%-34.61%-33.34%22.99B
-5.02%-3.32%+31.83%+7.10%14.63B
+0.92%+5.02%+59.09%-35.72%13.21B
+0.10%+1.18%-28.11%-24.41%12.72B
-6.86%+1.79%+285.66%+298.60%11.47B
-1.12%+1.97%-51.85%-63.73%9.98B
Average -1.39%-0.97%+40.07%+18.58% 26.29B
Weighted average by Cap. -1.16%-0.82%+37.30%+14.14%
See all sector performances

Financials

2024 *2025 *
Net sales 7.13B 7.53B 6.62B 5.91B 10.67B 639B 11.7B 82.14B 30.36B 262B 28.29B 27.65B 1,140B 7.68B 8.11B 7.12B 6.36B 11.49B 688B 12.59B 88.44B 32.69B 282B 30.46B 29.77B 1,227B
Net income 221M 233M 205M 183M 330M 19.77B 362M 2.54B 940M 8.12B 876M 856M 35.28B 607M 640M 563M 502M 907M 54.33B 995M 6.99B 2.58B 22.3B 2.41B 2.35B 96.93B
Net Debt 9.55B 10.07B 8.85B 7.9B 14.28B 855B 15.65B 110B 40.63B 351B 37.86B 37B 1,525B 8.97B 9.47B 8.32B 7.43B 13.42B 804B 14.71B 103B 38.2B 330B 35.59B 34.78B 1,434B
More financial data * Estimated data
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Employees
23,000
More about the company
Date Price Change Volume
24-12-09 8.804 +2.02% 1,497,471
24-12-06 8.630 -1.21% 1,228,194
24-12-05 8.736 +1.23% 2,294,515
24-12-04 8.630 +0.96% 2,327,005
24-12-03 8.548 +2.13% 2,187,947

Delayed Quote BME, December 09, 2024 at 11:35 am EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart GRIFOLS-S-AMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
8.804EUR
Average target price
16.68EUR
Spread / Average Target
+89.47%
Consensus

Quarterly revenue - Rate of surprise